secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001193125-24-211534
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics initiates registrational cohorts after positive Phase 1/2 DELIVER data; leadership changes
--------------------------------------------------------------------------------

- DYNE-251 (20 mg/kg Q4W) showed mean absolute dystrophin 3.71% of normal (unadjusted), >10x eteplirsen's 0.3% (cross-trial caution).
- Functional improvement in NSAA, SV95C (met EMA MCID), 10-MWR, Time to Rise from Floor; 10 mg/kg cohort improved from 6 to 12 months.
- Safety: favorable profile; no related SAEs except two at 40 mg/kg (resolved); >675 doses, >50 patient-years follow-up.
- Leadership: CMO Wildon Farwell resigned; hired Doug Kerr as CMO, Johanna Friedl-Naderer as CCO, Lucia Celona as CHRO; CBO and COO also resigning.
- Plans to update path to registration for DYNE-251 and DYNE-101 by end of 2024; ACHIEVE trial safety favorable up to 6.8 mg/kg Q8W.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/0001193125-24-211534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/d786894d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-211534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer